1-7 of 7
Luke Hughes-Davies
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO4-16-02: Can high progesterone receptor (PgR) expression identify tumours with low-risk tumour gene expression scores?

Robert Stein, Ralph Wirtz, Andrea Marshall, Jane Bayani, Sebastian Eidt, Claudia Schumacher, Hans-Peter Sinn, Andreas Schneeweiss, Andreas Makris, Iain Macpherson, Luke Hughes-Davies, Tammy Piper, Monika Sobol, Georgina Dotchin, Helen Higgins, Sarah Pinder, Abeer Shaaban, Janet Dunn, John MS Bartlett
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-16-02.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-16-02
Published: 02 May 2024
View article titled, Abstract PO4-16-02: Can high progesterone receptor (PgR) expression identify tumours with low-risk tumour gene expression scores?
Journal Articles

Abstract OT3-32-01: OPTIMA, a prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer

Robert Stein, Andreas Makris, Iain Macpherson, Luke Hughes-Davies, Andrea Marshall, Georgina Dotchin, David A. Cameron, Belinda E. Kiely, Caroline Wilson, Anne Armstrong, Helena M. Earl, Christopher J. Poole, Janice Tsang, Bjørn Naume, Daniel Rea, Hege Ohnstad, Peter S. Hall, Stuart A. McIntosh, Bethany Shinkins, Christopher McCabe, Adrienne Morgan, John MS Bartlett, Janet A. Dunn
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT3-32-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT3-32-01
Published: 01 March 2023
View article titled, Abstract OT3-32-01: OPTIMA, a prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer
Journal Articles

Abstract P3-10-05: Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients

Karen Pinilla Alba, Emma McMurtry, Anne-Laure Vallier, Louise Grybowicz, Ellen Copson, Anne Armstrong, Rebecca Roylance, Wendi Qian, Nikolaos Demiris, Stanly Thomas, Caron Harvey, Luke Hughes-Davies, Karen McAdam, Paula del Rosario, Bryony Harrop, Elena Provenzano, Marc Tischkowitz, Helena M Earl, Jean E Abraham
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P3-10-05.
https://doi.org/10.1158/1538-7445.SABCS19-P3-10-05
Published: 15 February 2020
View article titled, Abstract P3-10-05: Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Journal Articles

Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

Robert C Stein, Andrea Marshall, Andreas Makris, Luke Hughes-Davies, Iain R MacPherson, Carmel Conefrey, Leila Rooshenas, Sarah E Pinder, Abeer M Shaaban, Bjørn Naume, David A Cameron, Daniel W Rea, Helena M Earl, Christopher J Poole, Peter S Hall, Georgina Dotchin, Stuart A McIntosh, Victoria Harmer, Adrienne Morgan, Bethany Shinkins, Nigel Stallard, Christopher McCabe, Jenny L Donovan, John MS Bartlett, Janet A Dunn
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): OT3-17-01.
https://doi.org/10.1158/1538-7445.SABCS19-OT3-17-01
Published: 15 February 2020
View article titled, Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer
Journal Articles

Abstract PD2-3: ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer

Helena M Earl, Louise Hiller, Janet A Dunn, Clare Blenkinsop, Louise Grybowicz, Anne-Laure Vallier, Jean Abraham, Jeremy Thomas, Elena Provenzano, Luke Hughes-Davies, Karen McAdam, Stephen Chan, Rizvana Ahmad, Tamas Hickish, Stephen Houston, Daniel Rea, John Bartlett, Carlos Caldas, David Cameron, Larry Hayward
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): PD2-3.
https://doi.org/10.1158/1538-7445.SABCS14-PD2-3
Published: 01 May 2015
View article titled, Abstract PD2-3: ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer
Journal Articles

Abstract P4-11-07: Comparison of multiparameter tests in the UK OPTIMA-Prelim trial

John MS Bartlett, Robert C Stein, Jane Bayani, Andrea Marshall, Janet A Dunn, Amy F Campbell, Carrie Cunningham, Monika Sobol, Peter Hall, Leila Rooshenas, Adrienne Morgan, Christopher Poole, Sarah E Pinder, David A Cameron, Nigel Stallard, Jenny Donovan, Christopher McCabe, Luke Hughes-Davies, Andreas Makris, on Behalf of the OPTIMA Trial Management Group
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P4-11-07.
https://doi.org/10.1158/1538-7445.SABCS14-P4-11-07
Published: 01 May 2015
View article titled, Abstract P4-11-07: Comparison of multiparameter tests in the UK OPTIMA-Prelim trial
Journal Articles

Inhibiting Mutations in the Transforming Growth Factor β Type 2 Receptor in Recurrent Human Breast Cancer

Chris D. Lücke, Anna Philpott, James C. Metcalfe, Alastair M. Thompson, Luke Hughes-Davies, Paul R. Kemp, Robin Hesketh
Journal: Cancer Research
Cancer Res (2001) 61 (2): 482–485.
Published: 01 January 2001
View article titled, Inhibiting Mutations in the Transforming Growth Factor β Type 2 Receptor in Recurrent Human Breast Cancer
Open the PDF for Inhibiting Mutations in the Transforming Growth Factor β Type 2 Receptor in Recurrent Human Breast Cancer in another window